White House Withdraws Trump FDA Nominee Heidi Overton Before Senate Panel Vote
The White House on Tuesday withdrew Heidi Overton's nomination to lead the Food and Drug Administration, pulling the pick on the eve of a key Senate committee vote in Washington.[1]
Administration officials told senators that Overton asked former President Donald Trump to pull her name after it became clear she did not have enough Republican support to advance out of the Senate Health, Education, Labor and Pensions Committee.[1] The move cancels a committee vote that had been scheduled for Wednesday and forces the White House to accelerate vetting of alternative candidates or rely on an acting commissioner to run the agency for an extended period.[2]
The HELP Committee had been set to decide on Wednesday, November 18, whether to send Overton's nomination to the full Senate, a step that typically requires members of the president's party to unify behind the nominee.[2] Some Republican senators on the panel voiced unease about Overton's previous involvement in shaping administration policy on abortion pills and electronic cigarettes, and those concerns could not be settled before the planned vote, according to Republicans briefed on internal discussions.[1]
Overton's path had already appeared shaky earlier Tuesday, when CBS News reported that she was struggling to consolidate GOP support, an unusual dynamic for a president's own FDA nominee before a committee his party controls.[3] Later in the evening, CBS confirmed that the White House had dropped her nomination, citing a senior administration official and others familiar with the decision, after the withdrawal had first been reported by Axios.[2]
The failed nomination leaves the administration with a politically sensitive choice at an agency that oversees drug approvals, food safety and tobacco regulation, all flashpoints within the Republican Party.[1] Officials are considering whether to quickly put forward a new nominee who could face a Senate that may look different after next year's elections, or to lean on an acting commissioner while they search for a candidate who can unite both GOP factions and, potentially, enough Democrats to secure confirmation.[1]
Show source details & analysis (3 sources)
📌 Key Facts
- On Tuesday, November 17, 2026, the White House formally withdrew Heidi Overton's nomination to lead the Food and Drug Administration, doing so the night before a planned Senate committee vote.
- Administration officials told senators that Overton asked former President Trump to pull her nomination after it became clear she lacked sufficient Republican support to advance out of committee.
- The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on Overton's nomination on Wednesday, November 18, 2026, but the withdrawal canceled that vote.
- Some Republican senators on the Senate HELP Committee raised concerns about Overton's past roles in shaping policy on abortion pills and vaping, and those intra-party objections were not resolved before the scheduled vote.
- The withdrawal means the White House will begin vetting alternative candidates, including the possibility of naming a new nominee who might face a differently composed Senate next year.
- According to Fox News, the administration is weighing whether to move quickly with a new nominee or rely on an acting commissioner to run the FDA for an extended period.
- CBS News confirmed on November 17, 2026, that the White House dropped Dr. Heidi Overton's nomination as FDA commissioner, citing a senior administration official and others familiar with the decision.
- Axios was identified as the first outlet to report that Overton had been dropped as the administration’s nominee to lead the FDA.
📰 Source Timeline (3)
Follow how coverage of this story developed over time
- CBS News confirms on November 17, 2026, that the White House has dropped Dr. Heidi Overton's nomination as FDA commissioner, citing a senior administration official and other people familiar with the decision.
- The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on Overton's nomination on Wednesday, November 18, 2026.
- Axios is identified as the first outlet to report that Overton was dropped.
- On Tuesday, November 17, 2026, the White House formally withdrew Heidi Overton's nomination to lead the FDA, doing so the night before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote.
- Administration officials told senators that Overton asked President Trump to pull her nomination after it became clear she did not have enough Republican votes to be advanced out of committee.
- The withdrawal means the Senate HELP Committee will not hold the planned Wednesday vote and the White House will proceed with vetting alternative candidates, including a potential new nominee who could face a different Senate next year.
- Some GOP senators on the panel cited concerns over Overton's past roles in shaping policy on abortion pills and vaping, and Fox News reports those intra-party objections ultimately could not be resolved before the scheduled vote.
- The article notes that the administration is now weighing whether to move forward quickly with a new nominee or rely on an acting commissioner to run FDA for an extended period.